Office Locations
EUROPE & THE MIDDLE EAST
- Kyowa Kirin International plc (UK:
English) - Kyowa Kirin Ltd. (UK:
English) - Kyowa Kirin Pharma SAS (France)
- Kyowa Kirin Farmaceutica, S.L.U. (Spain:
Spanish) - Kyowa Kirin GmbH (Germany:
German) - Kyowa Kirin Sàrl (Switzerland:
German) - Kyowa Kirin Pharma B.V. (Netherlands:
Dutch) - Kyowa Kirin Pharma B.V. (Belgium + Luxembourg:
English) - Kyowa Kirin S.r.l. (Italy:
Italian) - Kyowa Kirin AB (Sweden:
Swedish) - Kyowa Kirin AB (Norway:
Norwegian) - Kyowa Kirin AB (Finland:
Finnish) - Kyowa Kirin AB (Denmark:
Danish) - Kyowa Kirin Pharma FZ-LLC (Dubai: English)
- Kyowa Kirin Pharma s.r.o. (Czech:
Czech)
JAPAN/ASIA PACIFIC
- Kyowa Kirin Co., Ltd. (Japan:
Japanese) - FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. (Japan:
Japanese /
English) - Kyowa Kirin plus Co,. Ltd. (Japan:
Japanese) - Kyowa Kirin Frontier Co., Ltd. (Japan:
Japanese) - Kyowa Kirin Asia Pacific Pte. Ltd. (
English ) - Kyowa Kirin China Pharmaceutical Co., Ltd. (China:
Chinese) - Kyowa Kirin Korea Co., Ltd. (Korea:
Korean) - Kyowa Kirin (Taiwan) Co., Ltd.(Taiwan:
Chinese) - Kyowa Kirin (Hong Kong) Co., Ltd. (Hong Kong:
Chinese /
English) - Kyowa Kirin (Thailand) Co., Ltd. (Thailand:
Thai) - Kyowa Kirin Australia Pty Ltd. (Australia:
English) - Kyowa Kirin Malaysia Sdn. Bhd. (Malaysia:
English)
Emerging Markets
In addition to the markets outlined above, Kyowa Kirin International works with local partners to ensure access to medicines for patients in 29 countries across the Central & Eastern Europe, Middle East & Africa (CEEMEA), North Africa and Latin America regions.
Kyowa Kirin wishes to thank the following partners for their continues collaboration to bringing medicines to patients with unmet need:
Copyright © Kyowa Kirin International plc. All rights reserved. This website is developed and funded by Kyowa Kirin International plc.
Kyowa Kirin International plc is a company registered in Scotland (company number SC198780) with registered address at Galabank Business Park, Galashiels TD1 1QH, United Kingdom.
KKI/INT/KKI/0917 September 2024
